Streetbeat News

Analyst Ratings

FRPT

Piper Sandler has reaffirmed its Overweight rating on Freshpet (NASDAQ:FRPT) and increased its price target from $88.00 to $100.00. Freshpet's shares are currently trading at $87.40, and the new price target suggests a potential upside of 14.42%. Freshpet Inc. is a company that produces natural fresh meals and treats for pets, distributed across various retail channels in North America and internationally.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:00 pm

BOH

Keefe, Bruyette & Woods has maintained its Underperform rating for Bank of Hawaii (NYSE:BOH) and lowered its price target from $57.00 to $55.00. Bank of Hawaii's shares are currently trading at $67.86, and the new price target suggests a potential decrease of 18.95%.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:00 pm

HWM

Keybanc has reaffirmed its Overweight rating on Howmet Aerospace (NYSE:HWM) and increased its price target from $52.00 to $60.00. Howmet Aerospace's shares are currently trading at $56.11, and the new price target suggests a potential upside of 6.93%. Howmet Aerospace operates in aerospace, commercial transportation, and other markets, offering innovative solutions like advanced airfoils and lightweight composite fasteners.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:00 pm

VIR

HC Wainwright & Co. has maintained a Buy rating for Vir Biotechnology (NASDAQ:VIR) but lowered its price target from $95.00 to $85.00. Despite the reduction, the new target suggests a significant upside of 770.9% from the current price of $9.76. Vir Biotechnology is a commercial-stage immunology company with a focus on infectious diseases and has multiple technology platforms and product candidates.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:00 pm

ARRY

Truist Securities analyst Jordan Levy has maintained a Buy rating on Array Technologies (NASDAQ:ARRY) but has reduced the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:59 pm

AMTX

Truist Securities analyst Jordan Levy has maintained a Hold rating on Aemetis (NASDAQ:AMTX) but reduced the price target from $5 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:57 pm

VRTX

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock price is currently $438.11, having dropped by 0.45% in the current market session. Despite this, VRTX has seen a 7.36% increase over the past month and a 38.81% rise over the past year. The article discusses the company's P/E ratio in comparison to the Biotechnology industry average, suggesting that VRTX's lower P/E might indicate it is undervalued or expected to perform worse than its peers. The P/E ratio, while useful, should not be the sole metric for investment decisions and should be used alongside other financial metrics and qualitative analysis.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:45 pm

LLY

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Eli Lilly (NYSE:LLY) and maintained a price target of $630.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:44 pm

JNJ

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Johnson & Johnson (NYSE:JNJ) with a maintained price target of $215.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:42 pm

RF

Stephens & Co. analyst Terry McEvoy has reiterated an Equal-Weight rating on Regions Financial Corporation (NYSE:RF) and maintained a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:33 pm